FGF21 and metabolic dysfunction-associated steatohepatitis: Preclinical studies with FGF21 analogs have shown promising effects, including inhibition of inflammation and immune cell infiltration in the liver, reduction in liver injury and hepatocyte death, significant improvement in liver fibrosis, and prevention of NASH/MASH development [51].